The temporary authorisation of telemedicine in Brazil will become permanent, HBI is told by a source close to the decision-making process, as the country's legislature is set to unveil a new law in Q4/1.
India's largest dialysis provider NephroPlus has acquired the fourth-largest private operator in the Philippines, while its home haemodialysis volumes have tripled during the pandemic in India, CEO Vikram Vuppala tells HBI.
UK Addiction Treatment claims 97% occupancy within a week of opening its latest facility. But would you invest in a business run by addicts for addicts? Or whose majority investor, Global Group, has recently seen its founder, Greg Lindbergh, jailed for bribing a US official? We talk to UKAT CEO, Eytan Alexander.
Intermediate Capital Group (ICG) is indirectly acquiring over 25% of the shares of Europe's largest radiopharmaceuticals provider Curium Pharma, HBI can reveal, after owner Capvest earlier pulled a majority sales process because of COVID-19.
Veritas Intercontinental, the spin-off of US genome sequencing group, Veritas Genetics, has raised €5m from existing investors to help finish building a new lab in Spain. CEO Javier de Echevarría tells HBI that the money will help to establish its independence from its former parent company which temporarily ceased US trading last year.
Swedish B2C telehealth player Kry has registered 14,000 patients in its first health care centre in Sweden, which comes as it's been forced into the capitated funding system. The start-up has been criticised for not making it clear enough to patients that they would be de-registered from their physical healthcare practice.
Valuations in the healthcare services sector will roughly stay the same post-COVID, according to a panel of investors from UBS, EQT, Icade Sante and TPG at a HBI-365 panel. That's despite the fact that HBI-365 delegates do not think that deal flow will return to pre-pandemic levels until the second half of next year.
HBI hears Synlab's private equity owner Cinven has mandated banks for an initial public offering, expected to take place next year. It will value Synlab at €5bn-6bn.
HBI speaks exclusively to George Spanos, chairman and CEO of Greece's largest primary care and diagnostic chain, about the company's plans for the future and whether rumours the company might be for sale are true.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.
